Classification under the Medical Device Regulation (MDR) is not a label to add later. It shapes the conformity route, the level of notified-body involvement, the documentation burden, the clinical evidence expectations, and the post-market obligations that follow.
Qmed helps manufacturers assess classification early and translate that decision into concrete project consequences. We look at intended purpose, how the device works, how and where it is used, whether it is invasive or active, how long it is used for, and where borderline questions could create risk later.
What this service covers
Support can include reviewing the device description and intended purpose, assessing the applicable MDR classification rules, challenging hidden assumptions, documenting the rationale, and explaining what the classification means for the wider programme.
That can be delivered as a focused classification assessment or as part of a broader regulatory strategy. Some teams need a clear answer on one question. Others need that answer connected to evidence planning, technical documentation, quality-system expectations, and market-access sequencing.
Why this matters early
One of the most common causes of avoidable rework is that a team moves forward on an assumed classification and only tests it properly once documentation, evidence planning, or partner discussions are already underway. By then, the knock-on effect is usually bigger and more expensive.
For startups, classification affects the path from funding to revenue. For experienced teams, it affects resourcing, review risk, and how quickly the next milestone can be approached with confidence.
Talk to Qmed
Tell us what your device is intended to do, how it’s used, and where the classification question is still unclear.